Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Halozyme Therapeutics stock

Own Halozyme Therapeutics stock in just a few minutes.

Halozyme Therapeutics, Inc is a biotechnology business based in the US. Halozyme Therapeutics shares (HALO) are listed on the NASDAQ and all prices are listed in US Dollars. Halozyme Therapeutics employs 136 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Halozyme Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HALO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Halozyme Therapeutics share price

Use our graph to track the performance of HALO stocks over time.

Halozyme Therapeutics shares at a glance

Information last updated 2021-04-29.
52-week range$22.11 - $56.40
50-day moving average $44.63
200-day moving average $42.14
Wall St. target price$49.20
PE ratio 55.967
Dividend yield N/A (0%)
Earnings per share (TTM) $0.91

Buy Halozyme Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Halozyme Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Halozyme Therapeutics under- or over-valued?

Valuing Halozyme Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Halozyme Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Halozyme Therapeutics's P/E ratio

Halozyme Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 56x. In other words, Halozyme Therapeutics shares trade at around 56x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Halozyme Therapeutics's EBITDA

Halozyme Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $145.8 million.

The EBITDA is a measure of a Halozyme Therapeutics's overall financial performance and is widely used to measure a its profitability.

Halozyme Therapeutics financials

Revenue TTM $267.6 million
Operating margin TTM 53.91%
Gross profit TTM $190 million
Return on assets TTM 15.74%
Return on equity TTM 106.33%
Profit margin 48.24%
Book value $1.12
Market capitalisation $7.3 billion

TTM: trailing 12 months

Shorting Halozyme Therapeutics shares

There are currently 7.0 million Halozyme Therapeutics shares held short by investors – that's known as Halozyme Therapeutics's "short interest". This figure is 9.5% down from 7.8 million last month.

There are a few different ways that this level of interest in shorting Halozyme Therapeutics shares can be evaluated.

Halozyme Therapeutics's "short interest ratio" (SIR)

Halozyme Therapeutics's "short interest ratio" (SIR) is the quantity of Halozyme Therapeutics shares currently shorted divided by the average quantity of Halozyme Therapeutics shares traded daily (recently around 1.2 million). Halozyme Therapeutics's SIR currently stands at 6. In other words for every 100,000 Halozyme Therapeutics shares traded daily on the market, roughly 6000 shares are currently held short.

However Halozyme Therapeutics's short interest can also be evaluated against the total number of Halozyme Therapeutics shares, or, against the total number of tradable Halozyme Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Halozyme Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Halozyme Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.057% of the tradable shares (for every 100,000 tradable Halozyme Therapeutics shares, roughly 57 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Halozyme Therapeutics.

Find out more about how you can short Halozyme Therapeutics stock.

Halozyme Therapeutics share dividends

We're not expecting Halozyme Therapeutics to pay a dividend over the next 12 months.

Halozyme Therapeutics share price volatility

Over the last 12 months, Halozyme Therapeutics's shares have ranged in value from as little as $22.11 up to $56.4. A popular way to gauge a stock's volatility is its "beta".

HALO.US volatility(beta: 1.41)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Halozyme Therapeutics's is 1.4137. This would suggest that Halozyme Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Halozyme Therapeutics overview

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F.

Frequently asked questions

What percentage of Halozyme Therapeutics is owned by insiders or institutions?
Currently 1.213% of Halozyme Therapeutics shares are held by insiders and 98.414% by institutions.
How many people work for Halozyme Therapeutics?
Latest data suggests 136 work at Halozyme Therapeutics.
When does the fiscal year end for Halozyme Therapeutics?
Halozyme Therapeutics's fiscal year ends in December.
Where is Halozyme Therapeutics based?
Halozyme Therapeutics's address is: 11388 Sorrento Valley Road, San Diego, CA, United States, 92121
What is Halozyme Therapeutics's ISIN number?
Halozyme Therapeutics's international securities identification number is: US40637H1095
What is Halozyme Therapeutics's CUSIP number?
Halozyme Therapeutics's Committee on Uniform Securities Identification Procedures number is: 40637H109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site